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Background: The effectiveness of intranasal (IN) fentanyl as an analgesic for painful pediatric limb injuries in the
Emergency Department (ED) has been reported previously. However, efficacy of IN ketamine in sub-dissociative
doses is not well studied in the ED setting. A non-blinded pilot study undertaken by this study group suggested
that IN ketamine showed similar analgesic effectiveness to that reported with IN fentanyl in similar non-blinded
studies. The aim of this randomized, controlled, equivalence trial is to compare the analgesic effect of sub-
dissociative dose IN ketamine with IN fentanyl for children with isolated musculoskeletal limb injuries.
Methods/Design: This is a prospective, randomized, controlled, double-blind equivalence trial of children
agedthree to thirteen years and less than 50 kg body weight, with isolated musculoskeletal limb injury, presenting
to the ED with moderate to severe pain, defined as a verbal response of at least six to a standard 11-point scale
(0 = none, 10 = worst pain imaginable). Pain score, sedation, satisfaction with analgesic intervention, and adverse
effects will be assessed over a 60 minute interval for each participant. Intranasal ketamine (1 mg/kg) or fentanyl
(1.5 microgram/kg) will be administered via blinded syringe and mucosal atomization device in a standardized
volume at 0.03 ml/kg, with a maximum volume of 1.5 ml divided equally to both nares. Participants will also
receive 10 mg/kg ibuprofen orally. The primary outcome measure will be median change in pain score from pre-
administration to 30 minutes post-administration. Non-parametric Mann–Whitney U tests will be computed to
compare median change in the primary outcome measure for IN ketamine and fentanyl. A sample size of 36
participants per group is needed to detect the expected 40 mm reduction in pain rating with a 95% confidence
interval (CI) no greater than ± 10 mm at 30 minutes. Rescue analgesia will be given as IN fentanyl or intravenous
morphine.
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Discussion: This is the first randomized-controlled trial comparing the efficacy of these two analgesic agents via
the intranasal route. If IN ketamine is found to be equally effective to IN fentanyl for this indication, it will provide
another analgesic agent that may be considered for the relief of acute pain in children in the ED.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12612000795897.
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Children with painful limb injuries frequently present to
hospital Emergency Departments (ED) [1]. Accordingly,
early and adequate provision of analgesia is considered a
fundamental component of quality patient care in the
ED [2]. The intranasal (IN) delivery of analgesic agents
provides quick and simple drug administration without
the need for needles [3], a particular advantage in
pediatric patients. Intranasal delivery of fentanyl is a
widely accepted pain relief strategy in children both in
the pre-hospital [4] and ED [5,6] settings.
Considered the current standard of care in Australian
EDs [6], advantages of IN fentanyl can be rapid break-
through pain treatment [7] comparable to intravenous
morphine [8], minimal sedation, and high relative bio-
availability [9]. Adverse events specifically attributed to
IN fentanyl are difficult to quantify in clinical trials [7],
yet patients may be exposed to usual adverse events of
opioid-related analgesia. Furthermore, IN fentanyl use is
limited due to concentration and dose volume. Intrana-
sal dose volume is, ideally, 0.2 to 0.3 mL per naris, up to
a maximum of 0.5 mL [10]. As most EDs only stock the
50 mcg/mL concentration [5], IN fentanyl can only be
administered to children up to approximately 50 kg be-
fore the introduced volume (0.75 ml) is too large for
each naris.
Ketamine is a N-methyl D-aspartate (NMDA) receptor
antagonist, in use since the 1960s as an anesthetic, am-
nesic and analgesic agent. It remains a popular general
anesthetic worldwide as it provides sedation without
compromising airway reflexes [11]. At sub-dissociative
doses, ketamine has been used for pre-operative sedation
[12] and analgesia [13] among pediatric patients with lit-
tle to no reports of adverse events. In a dose-finding
pilot study conducted in our tertiary pediatric ED [14]
IN ketamine (1 mg/kg) provided analgesia comparable
to that reported with IN fentanyl (1.5 mcg/kg) in chil-
dren with limb injuries [5]. Furthermore, adverse events
of IN ketamine were transient and non-severe with diz-
ziness (37%) and poor taste (27%) most commonly
reported.
Use of the IN route for the delivery of sub-dissociative
doses of ketamine for pain relief is a relatively novel con-
cept in the pediatric population and the analgesic re-
sponse is not well characterized. To our knowledge,there are no studies comparing the efficacy of IN fen-
tanyl to IN ketamine in children or adults. The primary
aim of this clinical trial is to compare the analgesic effi-
cacy of a sub-dissociative dose of IN ketamine with IN
fentanyl in pediatric patients presenting to the ED with
moderate to severe pain due to isolated musculoskeletal
limb injuries. It is hypothesized that IN ketamine and IN




This is a prospective, randomized, controlled, double-
blind equivalence trial. The trial will be conducted in the
ED of two Monash Health hospitals: Monash Medical
Center, a tertiary referral hospital at which the Pediatric
ED has an annual census of 29,000 patients; and
Dandenong Hospital, an urban district hospital at which
the general ED has an annual census of 57,000 patients,
of whom approximately 25% are children. Participant in-
clusion and exclusion criteria are shown in Table 1.
Randomization and storage
Forty numbered syringes will be block-randomized at
each site to contain either ketamine or fentanyl using a
four block-randomization table as described by Altman
and Bland (1999) [15]. Each syringe will be prepared as
allocated and the unique number will be recorded on
the patient prescription accompanying the syringe.
Study medications
Fentanyl citrate 50 mcg/ml (DBL Fentanyl, Hospira Pty
Ltd, Melbourne, Australia) and Ketamine 200 mg/ml
(KetalarW Hospira Pty Ltd, Melbourne, Australia). For
both fentanyl and ketamine, 3 ml syringes will be pre-
pared. Fentanyl syringes will be made by drawing up
1.5 mL of fentanyl citrate parenteral solution for injec-
tion (50 mcg/mL) into a 3 mL syringe. Ketamine syrin-
ges will be prepared by diluting 0.5 mL ketamine
parenteral solution (100 mg/mL) with 1.0 mL of sodium
chloride 0.9% to make a final concentration of 50 mg/
1.5 mL (33.3 mg/mL). The trial syringes will be given an
expiry of one week from manufacture. Four syringes of
the block-randomized batch will be prepared weekly by
the pharmacy at each hospital site. Each week, unused
Table 1 Inclusion and exclusion criteria of the ‘PICHFORK’ trial
Inclusion criteria Exclusion criteria
Children aged three to thirteen years and up to 50 kg body mass Inability to gain informed consent from parent or guardian
Children with an isolated musculoskeletal injury of the limb Treatment with serotonergic antidepressants, prior administration of
parenteral or IN analgesics or opioid analgesia, and opioid antagonist use
Reported pain severity greater than or equal to 6 in the standard 11-
point verbal rating scale (0 = none, 10 = worst pain imaginable) at triage
Children with allergy to ketamine, fentanyl, or ibuprofen
Children that would normally be considered for IN fentanyl
administration for analgesia at Monash Health EDs.
Aberrant nasal anatomy, acute or chronic nasal problems or nasal trauma
that may preclude adequate intranasal delivery
Presence of multiple trauma and/or head injury with loss of
consciousness, and/or cognitive impairment.
Note: Use of simple analgesia such as paracetamol or ibuprofen or inhalational methoxyflurance within four hours prior to ED arrival does not exclude
participation. ED emergency department, IN intranasal.
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pharmacy. Unused, expired syringes will be re-made
with the same numbers and drug allocations until all
syringe numbers are accounted for. Syringe production
rate may vary through the study period depending on
the recruitment rate.Measurement tools
Pain severity rating scales
Pain rating will be undertaken using a similar methodology
to that used in our pilot study [14]. The Faces Pain Scale -
Revised (FPS-R): for children aged three to six years, re-
quires choice of one of a line of six faces described as
progressing from ‘no pain’ at the left hand end, to ‘very
much pain’ at the right hand end. The faces are allocated
numerical ratings of 0, 20, 40, 60, 80 and 100 from left to
right. This rating is used for severity calculations at a single
time point, while change is recorded as positive for face se-
lection towards the left (less pain) and negative towards the
right (more pain).
Visual Analog Scale (VAS): for children aged seven
years and older, required marking of a standard 100 mm
line labeled ‘no pain’ at the left hand end and ‘worst pain
ever’ at the right hand end. The severity rating at a sin-
gle time point is the measurement (mm) from the left
hand end of the line. Change in severity is recorded as
positive for movement to the left (less pain) and negative
towards the right (more pain).Description of change in pain severity
The patient will be asked to describe change in pain severity
as; ‘a lot less’, ‘a little less’, ‘the same’, ‘a little more’ or ‘a lot
more’.Patient/parent/guardian satisfaction of pain change
The patient/parent/guardian will be asked to describe satis-
factions of pain severity change as; ‘satisfied’, ‘not satisfied’ or
‘no opinion’.Sedation
The description of sedation will incorporate assessment by
the medical staff member and the patient/parent/guardian.
The attending doctor will assess the degree of sedation using
the University of Michigan Sedation Scale (UMSS). This has
been validated previously in analgesic and sedation studies
in children [16]. The patient/parent/guardian will be asked
to subjectively describe the degree of sedation in their child
as; ‘too sedated’, ‘sedated enough’, ‘unchanged’ or ‘not sedated
enough’.
Procedure
On identification of an eligible patient (Table 1), the attend-
ing doctor will read a standardized verbal consent script to
the parent/guardian. On obtaining verbal consent, baseline
severity ratings and sedation score will be recorded. The
study medication will be obtained from the next numbered
study pack and administered intranasally using a mucosal
atomizer device (MADWWolf Troy Medical, Salt Lake City,
UT, USA). For analgesic dose-volumes equal to and less
than 0.5 mL, the entire dose will be administered in one
nare. Doses above 0.5 mL will be divided equally and admin-
istered to both nares. Oral ibuprofen (10 mg/kg) (FENPAED
AFT Pharmaceuticals Pty Ltd., Sydney, Australia) will then
be administered within the first 15 minutes of IN adminis-
tration of the study medication unless this drug has already
been given in the past four hours. The parent/guardian will
then be given the full written participant information to pro-
cure written consent for ongoing participation and data col-
lection. Review of need for additional analgesia will occur
across the 60-minute data collection period. If rescue anal-
gesia is needed, participation in the study will be terminated
at that time. Data collected to time of termination will be
retained and included in the statistical analyses. Rescue anal-
gesia will be either further IN fentanyl or intravenous mor-
phine depending upon the treating doctor’s preference.
Outcome measures
The primary outcome measure will be median reduction
in pain severity scores 30 minutes (T30) after study
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sures will include; VAS change in pain severity 15 and
60 minutes (T15, T60), subjective description of change
in pain severity, satisfaction of pain change, sedation, ad-
verse events, need for rescue analgesia at T15, T30 and
T60, and need for rescue analgesia at T15, T30 and T60.
Statistical analyses
Patient age, sex, and weight will be reported as median
with interquartile range or number and percentage and
compared using either Mann–Whitney U or Fisher’s
exact tests as appropriate. Pain severity at each time
point and change in severity between time points will be
reported as median millimeter (mm) with interquartile
range and compared using the Mann–Whitney U test.
Previous research supports combination of severity mea-
sures from the VAS and FPS-R [16]. The UMSS scores
will be reported as median with interquartile range and
compared using Mann–Whitney U test. Patient/parent
satisfaction and need for rescue medication will be
reported as number and percentage and compared using
Fisher’s exact test. Adverse events will be described as
type and incidence.
Sample size
The required sample size of 36 per group has been cal-
culated using the assumption that the desired primary
clinical outcome is that pain should be at least ‘a little’
better by 30 minutes post-study medication administra-
tion. Based on previous reports of response to analgesia
in children [14,17] we defined a successful response to
analgesia in this study as a reduction of VAS pain score
measurement of approximately 40 mm from baseline
with a 95% confidence interval (CI) no greater than 10.
To allow for some margin of error in the underlying as-
sumptions, the baseline sample size has been increased
by 10% to 42 patients per group.
Discussion
Scope of the trial
While a number of descriptive observational studies
have reported the analgesic effects of IN ketamine in
sub-dissociative doses in non-ED settings in adults, no
trials have compared the efficacy of ketamine to other
analgesic agents in a blinded fashion. There is a paucity
of literature describing the use of IN ketamine in acute
pain in the ED in either adults or children. As a result,
this study aims to assess the effectiveness of IN ketamine
and fentanyl in a systematic blinded fashion in the ED.
Strengths
Prior to our dose-finding study [14], the effectiveness of
IN ketamine in an ED population was unreported, with
inferences drawn from other populations. However,results of our initial un-blinded study in children with
limb injuries suggested that IN ketamine has the poten-
tial to be an effective analgesic agent in acute pain in
children. Confirmation of these observations in a
blinded and randomized fashion will provide a higher
level of evidence as to the potential efficacy of IN
ketamine.Limitations
This trial may be limited by selection bias as some par-
ticipants with eligible limb injuries may have already re-
ceived opioid analgesia prior to ED presentation. As a
result, this will be a non-consecutive, convenience data
set. Furthermore, we will not exclude children who have
received non-opioid oral analgesia in this study. Patients
with a pain score greater than 6/10 on presentation can
be assumed to have a failed response to non-opioid anal-
gesia and as a result, would normally require opioid an-
algesia for pain relief. However, it is likely that some
patients receiving non-opioid analgesia prior to presen-
tation may have a reduction in pain scores below those
that would allow recruitment in this study. This also has
the potential to prolong the recruitment period for our
target sample size.Ethical considerations
This clinical trial has the Human Research Ethics Commit-
tee (HREC) approval of Monash Health HREC Committee
B. The trial is registered with the Australian New Zealand
Clinical Trials Registry (ACTRN12612000795897). The trial
protocol has been reviewed by the Monash Health Drug
and Therapeutics committee. A trial safety monitoring com-
mittee has been incorporated into the study design to review
adverse event incidents and ongoing analgesic efficacy in the
trial.Summary
Provision of IN analgesia is a common practice for pediatric
patients in the ED. Currently, IN fentanyl is the medication
of choice based upon data form observational studies. We
aim to assess whether the efficacy of IN ketamine is compar-
able to that of IN fentanyl in children with moderate to se-
vere pain and isolated limb injuries. A positive result in this
study may result in considering the addition of ketamine as
an alternative analgesic to IN opioids in children with mod-
erate to severe pain in the ED setting.Trial status
Recruitment commenced in November 2012 for the 84
participants needed for the trial. It is anticipated recruit-
ment will be completed by the end of 2013.
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